newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) Longboard